PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V3024 - Common Stock
Bargain Hunters Take Note: Insider Cluster-Buying At CATX
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of...
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi)Prolonged progression-free...
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
CATX Stock Earnings: Perspective Therapeutics Beats EPS, Beats Revenue for Q2 2024
CATX stock results show that Perspective Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trialsOn track to advance multiple pre-IND assets into the clinic in...
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
3 Outperforming Stocks Surpassing Even Nvidia This Year
Given its performance in 2024, there are very few stocks outperforming Nvidia this year. Here are three of them.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering...
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
CATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024
CATX stock results show that Perspective Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...